You just clicked a link to go to another website. If you continue, you will leave this site and go to a site run by someone else.
Medtronic does not review or control the content on the other website, and we are not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site are not approved in the Indian Subcontinent.
Any and all information provided is intended for general overview. Viewers taking any decision based on the information provided herein are requested to seek professional advice.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations.
Click “OK” to confirm you are a Healthcare Professional.
Medtronic bladder control therapy delivers significant quality of life improvements for people with overactive bladder and symptom improvement for people with urinary retention.1,2 Take the quiz below to determine whether Medtronic bladder control therapy may be the next best step for you.
*Indicates required field.
Information on this site should not be used as a substitute for talking with your doctor. Always talk with your doctor about diagnosis and treatment information.
Siegel S, Noblett K, Mangel J, Griebling TL, Sutherland SE, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim® Therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2015;34:224–230. Article published online: January 10, 2014. DOI: 10.1002/nau.22544.
Van Kerrebroeck P et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. Journal of Urology. 2007;178:2029-2034.